FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234254101> ?p ?o ?g. }

• W4234254101 endingPage "1285" @default.
• W4234254101 startingPage "1277" @default.
• W4234254101 abstract "our previously reported multicenter, blinded, randomized, controlled study of two doses of interferon beta-lb (IFNB) in 372 patients demonstrated a reduction in relapse frequency and severity and in MRI activity. We now report the results of the continuation of that study. The median time on study was 46.0 months for the placebo arm, 45.0 months for 1.6 million international units (MIU), and 48.0 months for 8 MIU. IFNB had a persistent beneficial effect on exacerbation rate and MRI burden of disease and was relatively free of long-term side effects. There was a one-third reduction in exacerbation rate in the 8-MIU treatment arm, compared with placebo, in each of 5 years. Serial annual MRI was done in all patients, and 217 of the patients had either a fourth- or fifth-year scan. There was no significant progression of lesion burden in the 8-MIU arm in each successive year compared with baseline (at 4 years, <i>p</i> = 0.917), whereas a highly significant increase in lesion area occurred in the placebo arm (p = 0.0001). Among the 154 noncompleters, there was no systematic bias recognized that favored either treatment arm for the outcome measures of exacerbation rate, disability, or MRI activity. Dropouts in the placebo group had higher exacerbation rates and accumulation of MRI lesion burden than did dropouts in the other treatment arms, which probably reduced the power of the study to demonstrate treatment effects on these measures in the later years of the trial. Neutralizing antibodies to IFNB were detectable in 38% of patients by the third year and were associated with a significant attenuation of treatment effect on exacerbation rate. However, the reduction in exacerbation rate approached 50% in the antibody-negative 8-MIU group. For all patients, both baseline and end point lesion burden significantly correlated with disability. Increase in MRI lesion area was also significantly correlated with increase in disability over the course of the study, validating serial MRI as an outcome measure with clinical relevance. Since the 8-MIU treatment arm had significantly less lesion accumulation by MRI, a reasonable expectation is that IFNB will limit progression of disability. Confirmed disease progression occurred in fewer patients in the high-dose treatment arm (35%) than in the placebo arm (46%) (<i>p</i> = 0.096). These results support but do not establish an effect of IFNB in limiting progression of disability. This study was not originally powered to demonstrate a treatment effect on disease progression. At these levels of disability, more patients or longer follow-up, or both, would be required. Accordingly, additional clinical trials will be necessary to evaluate the role of IFNB in preventing disability." @default.
• W4234254101 created "2022-05-12" @default.
• W4234254101 date "1995-07-01" @default.
• W4234254101 modified "2023-10-16" @default.
• W4234254101 title "Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial" @default.
• W4234254101 doi "https://doi.org/10.1212/wnl.45.7.1277" @default.
• W4234254101 hasPublicationYear "1995" @default.
• W4234254101 type Work @default.
• W4234254101 citedByCount "744" @default.
• W4234254101 countsByYear W42342541012012 @default.
• W4234254101 countsByYear W42342541012013 @default.
• W4234254101 countsByYear W42342541012014 @default.
• W4234254101 countsByYear W42342541012015 @default.
• W4234254101 countsByYear W42342541012016 @default.
• W4234254101 countsByYear W42342541012017 @default.
• W4234254101 countsByYear W42342541012018 @default.
• W4234254101 countsByYear W42342541012019 @default.
• W4234254101 countsByYear W42342541012020 @default.
• W4234254101 countsByYear W42342541012021 @default.
• W4234254101 countsByYear W42342541012022 @default.
• W4234254101 countsByYear W42342541012023 @default.
• W4234254101 crossrefType "journal-article" @default.
• W4234254101 hasConcept C126322002 @default.
• W4234254101 hasConcept C141071460 @default.
• W4234254101 hasConcept C142724271 @default.
• W4234254101 hasConcept C168563851 @default.
• W4234254101 hasConcept C203014093 @default.
• W4234254101 hasConcept C204787440 @default.
• W4234254101 hasConcept C27081682 @default.
• W4234254101 hasConcept C2777014857 @default.
• W4234254101 hasConcept C2780640218 @default.
• W4234254101 hasConcept C2781156865 @default.
• W4234254101 hasConcept C71924100 @default.
• W4234254101 hasConceptScore W4234254101C126322002 @default.
• W4234254101 hasConceptScore W4234254101C141071460 @default.
• W4234254101 hasConceptScore W4234254101C142724271 @default.
• W4234254101 hasConceptScore W4234254101C168563851 @default.
• W4234254101 hasConceptScore W4234254101C203014093 @default.
• W4234254101 hasConceptScore W4234254101C204787440 @default.
• W4234254101 hasConceptScore W4234254101C27081682 @default.
• W4234254101 hasConceptScore W4234254101C2777014857 @default.
• W4234254101 hasConceptScore W4234254101C2780640218 @default.
• W4234254101 hasConceptScore W4234254101C2781156865 @default.
• W4234254101 hasConceptScore W4234254101C71924100 @default.
• W4234254101 hasIssue "7" @default.
• W4234254101 hasLocation W42342541011 @default.
• W4234254101 hasOpenAccess W4234254101 @default.
• W4234254101 hasPrimaryLocation W42342541011 @default.
• W4234254101 hasRelatedWork W2003938723 @default.
• W4234254101 hasRelatedWork W2047967234 @default.
• W4234254101 hasRelatedWork W2112264559 @default.
• W4234254101 hasRelatedWork W2118496982 @default.
• W4234254101 hasRelatedWork W2364998975 @default.
• W4234254101 hasRelatedWork W2439875401 @default.
• W4234254101 hasRelatedWork W2617222556 @default.
• W4234254101 hasRelatedWork W4238867864 @default.
• W4234254101 hasRelatedWork W2130939671 @default.
• W4234254101 hasRelatedWork W2525756941 @default.
• W4234254101 hasVolume "45" @default.
• W4234254101 isParatext "false" @default.
• W4234254101 isRetracted "false" @default.
• W4234254101 workType "article" @default.